JOHNSON & JOHNSON
For the period ended Dec 28, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
The Company's subsidiaries operate 63 manufacturing facilities occupying approximately 10.4 million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company’s business approximately as follows:
| Segment | Square Feet(in thousands) |
|---|---|
| Innovative Medicine | 5,245 |
| MedTech | 5,118 |
| Worldwide Total | 10,363 |
Within the U.S., three facilities are used by the Innovative Medicine segment and 19 by the MedTech segment. Outside of the U.S., 16 facilities are used by the Innovative Medicine segment and 25 by the MedTech segment.
The locations of the manufacturing facilities by major geographic areas of the world are as follows:
| Geographic Area | Number ofFacilities | Square Feet(in thousands) |
|---|---|---|
| United States | 22 | 3,037 |
| Europe | 22 | 5,035 |
| Western Hemisphere, excluding U.S. | 7 | 1,054 |
| Africa, Asia and Pacific | 12 | 1,237 |
| Worldwide Total | 63 | 10,363 |
In addition to the manufacturing facilities discussed above, the Company maintains numerous office, research and development and warehouse facilities throughout the world.
The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.
The Company is committed to maintaining all of its properties in good operating condition.
Segment information on additions to property, plant and equipment is contained in Note 17 Segments of business and geographic areas of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.